TG Therapeutics (TGTX) News Today $34.42 +4.33 (+14.39%) Closing price 04:00 PM EasternExtended Trading$34.20 -0.22 (-0.64%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period TG Therapeutics: A Wonderful HoldMarch 3 at 4:10 PM | seekingalpha.comTG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call TranscriptMarch 3 at 12:06 PM | seekingalpha.comInvestors Buy High Volume of TG Therapeutics Call Options (NASDAQ:TGTX)TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) saw some unusual options trading activity on Monday. Stock investors bought 13,927 call options on the stock. This is an increase of approximately 105% compared to the typical volume of 6,778 call options.March 3 at 11:35 AM | marketbeat.comTG Therapeutics Swings to Quarterly Profit, Targets Higher Revenue in 2025March 3 at 11:08 AM | marketwatch.comTG Therapeutics stock rises following upbeat Q4 earningsMarch 3 at 11:08 AM | in.investing.comTG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 3 at 11:08 AM | markets.businessinsider.comTG Therapeutics (NASDAQ:TGTX) Sees Strong Trading Volume After Earnings BeatTG Therapeutics (NASDAQ:TGTX) Sees Unusually-High Trading Volume Following Strong EarningsMarch 3 at 10:44 AM | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings ResultsTG Therapeutics (NASDAQ:TGTX - Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.06. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.March 3 at 9:13 AM | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPSTG Therapeutics (NASDAQ:TGTX - Get Free Report) announced its quarterly earnings data on Monday. The biopharmaceutical company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.06. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.March 3 at 8:37 AM | marketbeat.comTG Therapeutics Inc (TGTX) Q4 Earnings: EPS Data Not Provided, Revenue Surpasses Estimates at ...March 3 at 7:38 AM | gurufocus.comIllinois Municipal Retirement Fund Makes New $2.35 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)Illinois Municipal Retirement Fund purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 78,101 shares ofFebruary 28 at 4:28 AM | marketbeat.comLos Angeles Capital Management LLC Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)Los Angeles Capital Management LLC cut its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 40.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,117 shares of the bioFebruary 28 at 4:27 AM | marketbeat.comTG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual ForumFebruary 27, 2025 | globenewswire.comTG Therapeutics Inc (TGTX) Announces Upcoming Conference Call to Discuss 2024 Financial ResultsFebruary 26, 2025 | gurufocus.comTG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business UpdateFebruary 26, 2025 | globenewswire.comNew York State Common Retirement Fund Purchases 239,881 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)New York State Common Retirement Fund lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 403.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 299,396 shares of the biopharmFebruary 26, 2025 | marketbeat.comIFP Advisors Inc Buys 54,983 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)IFP Advisors Inc grew its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 178,547 shares of the biopharmaceutical company's stock after aFebruary 25, 2025 | marketbeat.comTG Therapeutics (TGTX) to Release Earnings on WednesdayTG Therapeutics (NASDAQ:TGTX) will be releasing earnings before the market opens on Wednesday, February 26.February 24, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Principal Financial Group Inc.Principal Financial Group Inc. boosted its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 830,184 shares of the biopharmaceutical company's stock after purchasing an additiFebruary 24, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 16.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,234 shares of the biopharmaceuticalFebruary 23, 2025 | marketbeat.comHussman Strategic Advisors Inc. Sells 63,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)Hussman Strategic Advisors Inc. trimmed its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 60.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,000 shares of the biopharmaceutical compFebruary 21, 2025 | marketbeat.comVenturi Wealth Management LLC Invests $271,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)Venturi Wealth Management LLC bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,000 shares of the biopharmaceutical compFebruary 21, 2025 | marketbeat.comVan ECK Associates Corp Invests $4.22 Million in TG Therapeutics, Inc. (NASDAQ:TGTX)Van ECK Associates Corp bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 140,154 shares of the biopharmaceutical company's stock, valued at approximatFebruary 20, 2025 | marketbeat.comTG Therapeutics Inc (TGTX) Announces Key Presentations on BRIUMVI at ACTRIMS Forum 2025February 19, 2025 | gurufocus.comStrategic Financial Concepts LLC Purchases Shares of 46,655 TG Therapeutics, Inc. (NASDAQ:TGTX)Strategic Financial Concepts LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 46,655 shaFebruary 19, 2025 | marketbeat.comTG Therapeutics (TGTX) to Release Quarterly Earnings on WednesdayTG Therapeutics (NASDAQ:TGTX) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comBraun Stacey Associates Inc. Buys Shares of 442,805 TG Therapeutics, Inc. (NASDAQ:TGTX)Braun Stacey Associates Inc. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 442,805 shares of the biFebruary 18, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Entropy Technologies LPEntropy Technologies LP trimmed its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 71.9% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,780 shares of the biopharmaceutical company's stock after selling 22,420 sharesFebruary 14, 2025 | marketbeat.com283,679 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Castellan GroupCastellan Group purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 283,679 shares of the biopharmaceutical company's stockFebruary 13, 2025 | marketbeat.comBleakley Financial Group LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)Bleakley Financial Group LLC bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,140 shares of the biopharmaceuFebruary 13, 2025 | marketbeat.comMaxCyte partners with TG Therapeutics on autoimmune cell therapyFebruary 12, 2025 | lse.co.ukBank of America Securities Sticks to Its Sell Rating for TG Therapeutics (TGTX)February 11, 2025 | markets.businessinsider.comStrategic Financial Concepts LLC Acquires New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Strategic Financial Concepts LLC acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 46,655 shares of the biopharmaceutical company's stock, valueFebruary 11, 2025 | marketbeat.comStratos Wealth Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)Stratos Wealth Advisors LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,000 shares of the biopharmaceutical compaFebruary 9, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five haveFebruary 8, 2025 | marketbeat.comTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC reduced its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,730 shares of the biopharmaceutical company's stock afFebruary 7, 2025 | marketbeat.comPrecision Wealth Strategies LLC Purchases Shares of 17,608 TG Therapeutics, Inc. (NASDAQ:TGTX)Precision Wealth Strategies LLC bought a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 17,608 shares of the biopharmaceutical company's stock, valFebruary 2, 2025 | marketbeat.com11,000 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Symphony Financial Ltd. Co.Symphony Financial Ltd. Co. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 11,000 shares of the biopharmaceutical company's stock, valuedFebruary 2, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Rating Lowered to Sell at StockNews.comStockNews.com downgraded shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday.January 31, 2025 | marketbeat.comConfidence in TG Therapeutics’ Growth: Buy Rating Affirmed Amid Solid Financial PerformanceJanuary 29, 2025 | markets.businessinsider.comTG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8% - Here's What HappenedTG Therapeutics (NASDAQ:TGTX) Trading Up 6.8% - Should You Buy?January 24, 2025 | marketbeat.comTG Therapeutics: Entering 2025 With Increased Investor ExpectationsJanuary 23, 2025 | seekingalpha.comAnalysts Issue Forecasts for TG Therapeutics FY2025 EarningsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for TG Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the biopharmaceutical compJanuary 22, 2025 | marketbeat.comAssenagon Asset Management S.A. Cuts Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)Assenagon Asset Management S.A. reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 39.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 103,080 shares of the biJanuary 22, 2025 | marketbeat.comTG Therapeutics: 2025 Revenues Will Smash ExpectationsJanuary 21, 2025 | seekingalpha.comTG Therapeutics FY2024 EPS Forecast Raised by HC WainwrightTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for shares of TG Therapeutics in a research report issued on Wednesday, January 15th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical compaJanuary 17, 2025 | marketbeat.comStrong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG TherapeuticsJanuary 16, 2025 | markets.businessinsider.comTG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade)January 16, 2025 | seekingalpha.comHC Wainwright Boosts Earnings Estimates for TG TherapeuticsTG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities researchers at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for shares of TG Therapeutics in a report released on Wednesday, January 15th. HC Wainwright analyst E. White now expects that the biopharmaceuticalJanuary 16, 2025 | marketbeat.comIs TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers?January 15, 2025 | insidermonkey.com Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address TGTX Media Mentions By Week TGTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TGTX News Sentiment▼0.740.71▲Average Medical News Sentiment TGTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TGTX Articles This Week▼205▲TGTX Articles Average Week Get TG Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Summit Therapeutics News Intra-Cellular Therapies News Viatris News Moderna News Dr. Reddy's Laboratories News Vaxcyte News Sarepta Therapeutics News Ascendis Pharma A/S News Qiagen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TGTX) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
